Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of General Surgery, The First Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
BMJ Open. 2021 Jan 17;11(1):e041931. doi: 10.1136/bmjopen-2020-041931.
Biliary colic (BC) is a severe pain associated with nausea and vomiting, which is the most common symptom among the gallstone population. This protocol proposes a methodology for conducting a systematic review and meta-analysis that aims to assess the benefits and safety of acupuncture in patients with BC.
Clinical trials will be identified through nine databases from inception to December 2020, using Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Allied and Complementary Medicine Database (AMED), CINAHL, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Database and Wanfang Database. Search words will be used for the BC and acupuncture. The analysis would include randomised, controlled, clinical trials of adults with BC that were published in either Chinese or English. The primary outcome is to measure pain relief. Two or three reviewers should be in charge of study selection, data extraction and evaluating the risk of bias. RevMan software (V.5.4) will be used to perform the assessment of the risk of bias and data synthesis.
Ethics approval will not be required for this review, as it will only involve the collection of literature previously published. The results of this meta-analysis will be disseminated in a peer-reviewed journal or relevant conference, through publication.
CRD42020167510.
胆绞痛（BC）是一种伴有恶心和呕吐的严重疼痛，是胆石症人群中最常见的症状。本方案提出了一种系统评价和荟萃分析的方法，旨在评估针刺治疗 BC 患者的疗效和安全性。
将从建库至 2020 年 12 月，通过 9 个数据库（Cochrane 中央对照试验注册库（CENTRAL）、MEDLINE、Embase、辅助和补充医学数据库（AMED）、CINAHL、中国知网（CNKI）、中国生物医学文献数据库（CBM）、维普数据库和万方数据库）检索临床试验。检索词将用于 BC 和针灸。分析将包括成人 BC 的随机对照临床试验，无论其发表于中文还是英文。主要结局指标是衡量疼痛缓解程度。应由 2 或 3 位评审员负责研究选择、数据提取和评估偏倚风险。RevMan 软件（V.5.4）将用于评估偏倚风险和数据综合。
本综述不需要伦理批准，因为它只涉及以前发表的文献的收集。荟萃分析的结果将在同行评议的期刊或相关会议上发表，以发表的形式传播。
CRD42020167510。
